Aparna Parikh

1.6k total citations
15 papers, 37 citations indexed

About

Aparna Parikh is a scholar working on Surgery, Oncology and Cancer Research. According to data from OpenAlex, Aparna Parikh has authored 15 papers receiving a total of 37 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 6 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Aparna Parikh's work include Cancer Genomics and Diagnostics (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Protein Tyrosine Phosphatases (3 papers). Aparna Parikh is often cited by papers focused on Cancer Genomics and Diagnostics (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Protein Tyrosine Phosphatases (3 papers). Aparna Parikh collaborates with scholars based in United States, Tanzania and Italy. Aparna Parikh's co-authors include Jing Xu, Jennifer Y. Wo, Theodore S. Hong, Jill N. Allen, Jeffrey W. Clark, David P. Ryan, Heather A. Shahzade, Christine A. Ulysse, W. Marston Linehan and Janet E. Murphy and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Aparna Parikh

13 papers receiving 36 citations

Peers

Aparna Parikh

ONCOL

PRM

SURGE

EPIDE

Brij Bhushan Tyagi India

Ebert Poquioma Peru

Corinna Slawinski United Kingdom

Fariborz Mansour-Ghanaei Iran

Monika A. Zelazowska United States

Emily Howe United States

Sylvia Wright United Kingdom

Jaime Siegrist Spain

J.-P. Arnault France

Kornelius Schulze Germany

Brij Bhushan Tyagi India

Aparna Parikh

17 ×1.0

ONCOL

7 ×0.5

PRM

11 ×1.1

SURGE

9 ×1.0

7 ×0.9

EPIDE

Citations per year, relative to Aparna Parikh Aparna Parikh (= 1×) peers Brij Bhushan Tyagi

Countries citing papers authored by Aparna Parikh

Since Specialization

Citations

This map shows the geographic impact of Aparna Parikh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aparna Parikh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aparna Parikh more than expected).

Fields of papers citing papers by Aparna Parikh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aparna Parikh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aparna Parikh. The network helps show where Aparna Parikh may publish in the future.

Co-authorship network of co-authors of Aparna Parikh

This figure shows the co-authorship network connecting the top 25 collaborators of Aparna Parikh. A scholar is included among the top collaborators of Aparna Parikh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aparna Parikh. Aparna Parikh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Gimeno-Valiente, Francisco, Diego González, Susana Roselló, et al.. (2025). Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis. Cancer Treatment Reviews. 142. 103066–103066. 1 indexed citations

Riedl, Jakob M., Bennett Adam Caughey, Hideo Matsubara, et al.. (2024). 68O Frequency of clinical acquired RAS-MAPK pathway resistance alterations in patients treated with KRASG12C inhibitors: An individual patient meta-analysis. Annals of Oncology. 35. S241–S241.

McKean, Meredith, Ezra Y. Rosen, Minal Barve, et al.. (2023). Abstract CT184: Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: a phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors. Cancer Research. 83(8_Supplement). CT184–CT184. 5 indexed citations

Corcoran, Ryan B., Ju Tian, J. Chen, et al.. (2022). SO-38 Clinical efficacy and single-cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients. Annals of Oncology. 33. S373–S373.

Michelakos, Theodoros, Yurie Sekigami, Filippos Kontos, et al.. (2021). Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Journal of Gastrointestinal Surgery. 25(11). 2859–2870. 7 indexed citations

Jankú, Filip, Eric J. Sherman, Rona Yaeger, et al.. (2021). Abstract CT212: Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF. Cancer Research. 81(13_Supplement). CT212–CT212. 1 indexed citations

Visrodia, Kavel, Brenna Casey, Jeffrey W. Clark, et al.. (2021). Safety and Feasibility of Same-session Endoscopic Ultrasound-guided Biopsy and Fiducial Placement in Pancreatic Cancer. Techniques and Innovations in Gastrointestinal Endoscopy. 23(2). 139–144. 1 indexed citations

Wo, Jennifer Y., Jeffrey W. Clark, Eric Roeland, et al.. (2019). A Pilot Study of Neoadjuvant FOLFIRINOX followed by Chemoradiation for Gastric and Gastroesophageal Cancer: Preliminary Results and Prognostic Implications of ctDNA. International Journal of Radiation Oncology*Biology*Physics. 105(1). S85–S86. 2 indexed citations

Wo, Jennifer Y., Edgar Ben‐Josef, B.Y. Yeap, et al.. (2018). A Pilot Feasibility Study of Definitive Concurrent Chemoradiation with Pencil Beam Scanning Proton Beam in Combination with 5-fluorouracil and Mitomycin-c for Carcinoma of the Anal Canal. International Journal of Radiation Oncology*Biology*Physics. 102(3). S63–S63. 2 indexed citations

10.

Parikh, Aparna, Lipika Goyal, Mehlika Hazar-Rethinam, et al.. (2017). Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. Annals of Oncology. 28. iii137–iii137. 5 indexed citations

11.

Mmbaga, Elia J., Li Zhang, Aparna Parikh, et al.. (2016). A Case-Control Study to Evaluate the Etiology of Esophageal Cancer in Tanzania. Journal of Global Oncology. 2(3_suppl). 5s–5s. 2 indexed citations

12.

Hopson, Sari, et al.. (2016). Is there a relationship between self-reported healthy days and comorbidity medication adherence among oncology patients?. Journal of Clinical Oncology. 34(7_suppl). 189–189. 2 indexed citations

13.

Desmond, Ronan, Barbara Weinstein, Aparna Parikh, et al.. (2015). 56 ELTROMBOPAG FOR LOW TO INTERMEDIATE-2 RISK MYELODYSPLASTIC SYNDROME. Leukemia Research. 39. S26–S27. 3 indexed citations

14.

Khalilzadeh, Omid, Bastian O. Sabel, Yongjin Sung, et al.. (2014). Temporal Evolution of Intraparenchymal Hyperdensity After Intra-arterial Therapy in Patients with Ischemic Stroke: Optimal Discrimination Between Hemorrhage and Iodinated Contrast. Clinical Neuroradiology. 24(4). 365–371. 3 indexed citations

15.

Parikh, Aparna, et al.. (2012). P235 Long-term clinical experience with vedolizumab (VDZ) in patients with mild to moderate ulcerative colitis (UC). Journal of Crohn s and Colitis. 6. S103–S103. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact